Getting to Know the New JAKs on the Block: Pharmacy-Focused Insights for Atopic Dermatitis and Alopecia Areata

This activity provides targeted education to community pharmacists and managed health care professionals for the emerging therapies on the horizon in moderate-to-severe atopic dermatitis (AD) and alopecia areata (AA). Also included are brief vignettes of actual patient interviews. Their perspectives will provide insight into the daily challenges and quality of life issues that can occur while living with AD and AA.

Our experts discuss the connection between AD and AA and compare/contrast their differences; the challenges surrounding the available treatments for AD and AA, with a large unmet need for alternative and more effective therapies with a good safety profile for long-term use; how the Janus kinase (JAK)-signal transducer activator of transcription pathways have an important role in the pathogenesis of AD and AA; the latest clinical trial efficacy, safety, and tolerability data of available and emerging oral JAK inhibitors currently under investigation for AD and AA; and the potential place in therapy and monitoring aspects for the emerging agents in AD and AA.

Furthermore, the experts discuss how the health disparities of patients with AA and/or AD leads to lower medication access and they explore the unique role of the pharmacist in providing education and obtaining prior authorization to medications for patients with AA and/or AD.

Target Audience

This curriculum is intended for a broad audience of community pharmacists, dermatologic specialty pharmacists, and managed health care professions involved in the care and treatment of patients with AD and/or AA.

Learning Objectives

After completing this activity, participants should be able to:

  1. Explore the changing paradigm of Alopecia Areata (AA) and Atopic Dermatitis (AD) disease presentation and treatment approach.   
  2. Assess and interpret the latest clinical trial data among emerging oral agents in AA and/or AD and terms of therapeutic target, safety, efficacy, and tolerability.
  3. Recognize the potential place in therapy and monitoring aspects for the emerging agents in AA and AD in order to effectively engage patients in shared decision-making for their treatment plan.
  4. Outline a plan to proactively identify and remove barriers for health maintenance services and medication access in underserved patients with AA and/or AD.


This program is supported by an educational grant from Pfizer. 

Course summary
Available credit: 
  • 1.75 ACPE Pharmacy
Course opens: 
Course expires: 


The University of Rhode Island College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This is an application-based educational activity. Pharmacists will receive 1.75 contact hour (0.175 CEUS) for the educational activity. No partial credit is available. Initial Release Date: October 30, 2021. Planned Expiration Date: October 30, 2022.

UAN: 0060-9999-21-053-H01-P

Available Credit

  • 1.75 ACPE Pharmacy
Please login or register to take this course.